The had been no effective treatment for people who suffer from tardive dyskinesia. So this announcement is potentially huge, and the drug is not even on the market yet.
People who suffer from tardive dyskinesia are highly aware of their appearance, and so too are their families, and the medical staff that work with these patients. Anything that can significantly reduce the effects of tardive on patients, provided it is proven safe, will be highly, highly sought out, simply because there is nothing in the marketplace that does currently.
If you're holding this stock, Congratulations!!! You have a winner. If you're short the stock, you have a problem.